Navigation Links
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients With Multiple Sclerosis
Date:4/29/2009

dribine Tablets for registration to the European Medicines Agency (EMEA) and to the US Food and Drug Administration (FDA) in mid-2009.

(1) CLARITY: CLAdRIbine Tablets Treating MS OrallY

About the CLARITY study

The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled, international trial. It randomized 1,326 patients with relapsing-remitting MS according to the revised McDonald criteria2. Study participants were randomized to one of three different treatment groups consisting of two different dose regimens of Cladribine Tablets or matching placebo tablets (1:1:1 ratio). Cladribine Tablets were given in two or four treatment courses in the first year, with each course consisting of once daily administration for four to five consecutive days, which means study patients took Cladribine Tablets for 8 to 20 days during the year. In the second year, two treatment courses were administered to all patient groups. The primary endpoint of the CLARITY study was the qualifying relapse rate at 96 weeks. Secondary endpoints included MRI endpoints, proportion of subjects qualifying relapse-free and disability progression at 96 weeks. Out of the 1,326 randomized patients, 90% of patients treated with Cladribine Tablets completed the study (92% in the lower total dose group and 89% in the higher total dose group) compared to 87% in the placebo group.

About Cladribine Tablets

Merck Serono's proprietary oral formulation of cladribine (Cladribine Tablets) is currently being evaluated in Phase III as a treatment for patients with relapsing forms of multiple sclerosis (MS). Cladribine is a small molecule that may interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.

The clinical development program for cladribine tablets includes:


'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. The Lancet Publishes Two-Year Results of Abbotts Fully Bioabsorbable Drug Eluting Stent
2. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
3. Two-Year Follow-Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System
4. XTENT Announces Positive Two-Year CUSTOM I and One-Year CUSTOM II Trial Data for Novel Drug-Eluting Stent System
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
7. Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
8. Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy
9. Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
10. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
11. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Today,s New ... "Plan for Kidney Drugs Spurs Division," illustrates an ... in kidney patients continuing to be deprived of ... Medicare program limit. ,, As Congress is poised ... preserve the lives of transplant kidney recipients, behind-the-scenes ...
(Date:12/15/2009)... Dec. 15 Reportlinker.com announces ... is available in its catalogue: ,, ... Industry in the U.S. and its ... ,, http://www.reportlinker.com/p0167745/Surgical-and-Medical-Instrument-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html ,, The ... and Medical Instrument Manufacturing Industry report ...
(Date:12/15/2009)... YORK, Dec. 15 Reportlinker.com announces ... available in its catalogue: ,, Boehringer ... http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html ,, Introduction ,, ... performance for Boehringer Ingelheim in the Rx ... portfolio and pipeline analysis and assessment of ...
Breaking Medicine Technology:AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 2Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 3Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 4Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 5Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 6Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile 7BioConference Live Kicks off Three Day Online Event for Life Science and Biotech Communities Today at 9 3A00 AM Eastern 61505 1BioConference Live Kicks off Three Day Online Event for Life Science and Biotech Communities Today at 9 3A00 AM Eastern 61505 2BioConference Live Kicks off Three Day Online Event for Life Science and Biotech Communities Today at 9 3A00 AM Eastern 61505 3Obesity Rates Will Continue to Increase Drive Health Care Costs in New Jersey in Next Decade According to New Study 61501 1Obesity Rates Will Continue to Increase Drive Health Care Costs in New Jersey in Next Decade According to New Study 61501 2Vivakor Inc Announces Stock Dividend 14870 1Vivakor Inc Announces Stock Dividend 14870 2Vivakor Inc Announces Stock Dividend 14870 3Vivakor Inc Announces Stock Dividend 14870 4
... ,hotspots, linked to psoriasis ANN ARBOR, Mich., Jan. 25 ... of Dermatology , the U-M School of Public Health ... reveal how genetic differences among individuals result in psoriasis, an ... , the findings could lead to new drug targets and ...
... N.Y. and PRINCETON, N.J., Jan. 22 The ... Inc. today announced a partnership to support Phase ... (Cytarabine:Daunorubicin) Liposome Injection for treatment of adults with ... provide $3.7 million to support Celator,s Phase 2B ...
Other Medicine Technology:Scientists Unmask Genetic Markers Associated With Psoriasis 2Scientists Unmask Genetic Markers Associated With Psoriasis 3Scientists Unmask Genetic Markers Associated With Psoriasis 4The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML 2The Leukemia & Lymphoma Society and Celator Pharmaceuticals Announce Partnership to Accelerate Development of CPX-351 for AML 3
(Date:12/15/2009)... For Preserving State Authority, Ban on Annual Benefit ... Dec. 15 Consumer Watchdog condemned the ... over 55 and the public option from the ... said that the Senate must still make three ... prevent ceding the entire health care system to ...
(Date:12/15/2009)... donated to the Lupus Foundation of America and the ... 15 Julian Lennon, son of the legendary ... new digital single, "LUCY," to raise funds for research ... 2010, 100 percent of the proceeds from downloading "LUCY" ... of America (LFA), and the Saint Thomas, Lupus Trust ...
(Date:12/15/2009)... ,we would have really been in trouble, expert says ... of the pandemic H1N1 swine flu has revealed serious ... health emergencies, a new report says. , The report, ... Robert Wood Johnson Foundation, also finds the dire economy ... "The 2009 H1N1 outbreak is the latest in a ...
(Date:12/15/2009)... -- Knowledge Networks is significantly ... bio-tech research market with the acquisition of ... 11 years CMR has built and grown ... which now includes 70,000 U.S. physicians, and ... and hard-to-reach specialties. The Mount-Arlington, NJ-based ...
(Date:12/15/2009)... The new compact LifeSpan TR200 folding treadmill, made by ... was highly praised by treadmill review groups in recent ... TR200 folding treadmill received awards for Best New Treadmill, ... ,, The compact LifeSpan TR200 treadmill is designed for ... category buster is a very compact treadmill that could ...
Breaking Medicine News(10 mins):Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 2Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 3Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 4Health News:The 'Big 3' Fixes for the Weakened Senate Health Reform Bill to Block Full Insurance Co. Take-Over of Health System 5Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 2Health News:Serious Gaps Revealed in U.S. Response to Health Emergencies 3Health News:Knowledge Networks Expands in Pharma Research With Acquisition of CMR 2Health News:Treadmill Reviews Rate Compact LifeSpan Treadmill Best Treadmill 2
... study finds , , WEDNESDAY, Jan. 30 (HealthDay News) ... appear to benefit from high doses of the chemotherapy ... nervous system lymphoma (PCNSL) is a type of non-Hodgkin ... very difficult to treat, it can be cured or ...
... Blue Cross and Blue Shield of,Minnesota Foundation ... 13-member board,of directors. The board directs the ... health in Minnesota and includes five,community representatives., ... brings great experience and passion in working ...
... Jan. 30 The Senate,s Special,Committee on Aging, ... the assistance of the Center for Aging Services ... on some of the latest,innovations in services for ... technology for the aging and current,technology consumers discussed ...
... serious, potentially life-threatening disease that affects red blood cells, ... As part of the SardiNIA Study of Aging, supported ... of the National Institutes of Health, scientists have found ... explain why some people with beta-thalassemia seem to be ...
... a known risk factor for prostate cancer, and a new ... against cadmium. , In an article published in the February ... that PSA levels were 22 percent higher among American men ... mg/daily) and cadmium levels above the median. (PSA is a ...
... bog outshines 19 commonly eaten fruits for the ... latest,Agricultural Research Service Report from USDA, containing the ... foods, shows cranberries,score among the highest of all ... The report includes antioxidant values for a ...
Other Medicine News:Health News:High-Dose Chemo Helps Beat Rare Brain Cancer 2Health News:High-Dose Chemo Helps Beat Rare Brain Cancer 3Health News:Fernandez Appointed to Blue Cross Foundation Board 2Health News:Capitol Hill Briefing Features Technologies That Could Transform the Lives of Seniors 2Health News:Capitol Hill Briefing Features Technologies That Could Transform the Lives of Seniors 3Health News:Gene variant linked to moderated symptoms of beta-thalassemia 2Health News:Researchers investigate links between prostate, cadmium, zinc 2Health News:Cranberries' Antioxidant Level Tops List in USDA Report 2Health News:Cranberries' Antioxidant Level Tops List in USDA Report 3
Used for emergency airway access when endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
Used for emergency airway access when conventional endotracheal intubation cannot be performed. Supplied sterile in peel-open packages. Intended for one-time use....
... steel. Lamp supplied with blade. Rusch ... quality standard incandescent laryngoscope blades. The ... continually refined through many years of ... maintenance requirements. They are manufactured to ...
... Snap-Light™ laryngoscope blades are designed with the ... optic bundle can be removed to simplify ... reach areas. Our unique snap-on mechanism eliminates ... focused blades are interchangeable with other green ...
Medicine Products: